.png)
We are excited to announce the appointment of Dr. Ferenc Tracik as Neumirna’s Chief Medical Officer (CMO).
Dr. Tracik is a physician with more than two decades of experience leading drug development programs in neurological and rare diseases, including executive roles at NeuroSense Therapeutics, Biogen, Novartis and Teva.
Most recently, as CMO at NeuroSense Therapeutics, Dr. Tracik led global Phase 2 and pivotal Phase 3 programs in ALS and Alzheimer’s disease, including a successful IND submission to the FDA and positive Phase 2 results.
“Neumirna has reached an inflection point: the question is no longer whether the science works, but how quickly we can translate it into an option for patients with urgent unmet need,” said Ellen Donnelly, CEO of Neumirna. “Ferenc has the experience to get us there. Alongside his leadership in CNS development and global regulatory strategy, he has taken an ASO therapy for a neurological disease to patients.”
Dr. Tracik previously served as Vice President, Europe, Canada and Partner Markets at Biogen, where he led the European medical launch of an antisense oligonucleotide (ASO) for Spinal Muscular Atrophy (SMA). He also established a highly recognized multinational SMA registry in collaboration with leading experts and contributed to one of the largest global Expanded Access Programs in SMA.
At Neumirna, Dr. Tracik will be responsible for the medical and clinical strategy, focused on patient safety, regulatory interactions and external medical affairs. He will partner with Neumirna’s CDO to ensure a successful path for NMT.001 to the clinic in early 2027 and will also bring research and clinical expertise to Neumirna’s preclinical program in Parkinson’s disease.
"Antisense oligonucleotides are increasingly showing their potential to address underlying disease biology in neurological disorders, including through microRNA modulation," said Dr. Tracik. "Neumirna's approach holds promise for patients with high unmet medical need, and I look forward to translating this science into clinical impact together with the team."
Dr. Tracik holds an MD from Universität Regensburg, where his doctoral research focused on sleep disturbances in Parkinson's disease.
.png)